Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus

Abstract

Treatment strategies for esophageal adenocarcinoma patients continue to advance with the generation of more data from clinical trials that are permitting us to refine the use of immunotherapy in combination with other treatment modalities. While the frontline therapy for metastatic esophageal adenocarcinoma has become more complicated with the approval of combination regimens, it is also yielding better outcomes. These treatment strategies can now be individualized to fit patient circumstances and goals as well as the biomarker profile of their individual tumors leading to an increased likelihood of treatment related remissions and extended median survivals. Comprehensive genomic profiling at diagnosis should now be standard to allow the management team to customize each patient’s treatment plan based on the genetic abnormalities discovered in their tumor. By refining these targeted approaches, we will see decreased toxicities and increased survival.